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Abstract
SARS-CoV-2 is the causative agent of COVID-19, an emergent zoonotic disease which 
has reached pandemic levels and is designated a public health emergency of 
international concern by the World Health Organisation. Early data suggest that older 
age, male sex and a diagnosis of hypertension or diabetes independently increase the 
risk of hospitalisation and death from COVID-19; however, the biological mechanisms 
underpinning these associations are currently unclear. T he SARS-CoV-2 virus enters 
human cells through the ACE2 receptor. Current and past tobacco smoking is 
associated with changes in the ACE2 receptor expression, hypertension, diabetes and 
worse outcomes following other viral infections. It is hence plausible that smoking is 
an independent risk factor for hospitalisation and death from COVID-19. Here, we 
review available evidence for an association between smoking status and 
hospitalisation for COVID-19. We highlight concerns regarding the quality of available 
data and call for more systematic collection of smoking status in future studies.
Large age and gender differences in case severity and mortality have been observed in
the ongoing COVID-19 pandemic[1]​; these differences are currently unexplained. Early
evidence suggests that hypertension and diabetes are key risk factors for heightened
morbidity and mortality from COVID-19.
 
SARS-CoV-2 has been shown to enter epithelial cells through the ACE2 receptor[2]​. Some
evidence suggests that gene expression and subsequent receptor levels are elevated in
the airway and oral epithelium of current smokers[3]​[4]​[5]​, thus putting smokers at higher
risk of contracting SARS-CoV-2. Other studies, however, show that nicotine
downregulates the ACE2 receptor[6]​. T hese uncertainties notwithstanding, both past and
Qeios, CC-BY 4.0   ·   Article, April 1, 2020
Qeios ID: VGJCUN   ·   https://doi.org/10.32388/VGJCUN 1/6
current smoking is known to increase the risk of respiratory viral[7]​[8]​ and bacterial[9]​[10]​
 infections and is associated with worse outcomes once infected. Cigarette smoke
reduces the respiratory immune defence through peri-bronchiolar inflammation and
fibrosis, impaired mucociliary clearance and disruption of the respiratory epithelium[11]​.
T here is also reason to believe that behavioural factors (e.g. regular hand-to-mouth
movements) involved in smoking may increase SARS-CoV-2 transmissions as has been
observed for other viruses[12]​. However, early data from the COVID-19 pandemic have
not provided clear evidence for a negative impact of smoking on COVID-19 related
outcomes, such as hospitalisation or mortality[13]​.
 
Available data from China suggest a lower than expected number of hospital admissions
among the smoking population. Crude (non age-stratified) smoking prevalence in China is
reported at 54% among men and 2.6% among women[14]​; however, a review of 8
Chinese studies with data on smoking status suggest fewer hospitalised smokers than
would be expected from national prevalence estimates[15]​. T he largest of these studies
presented smoking status for 1085 patients hospitalised with COVID-19[1]​. 12.6% were
current smokers, 1.9% past smokers and 85.4% were never smokers. Current and past
smokers had worse outcomes (defined as IT U admission or death) than never smokers
at 12%, 24% and 4.8%, respectively. T wo further studies presented smoking status for
191 and 140 hospitalised patients, respectively. In the first study[16]​, 11 individuals (5.8%)
were identified as current smokers with 6 surviving until discharge. T he second study
reported 2 current (1.4%) and 7 past (5%) smokers with severe disease[17]​. Five further
studies[18]​[19]​[20]​[21]​[22]​ identified 46 current or past smokers in a combined population of
386 hospitalised patients. Across these studies, data were presented for 1,690 admitted
patients, 56 of whom (3.3%) were identified as being current or past smokers.
 
T hese early studies are limited by a number of factors. First, they describe populations
admitted to intensive care in the context of an emerging epidemic; hence, it is likely that
data collection on smoking status was not considered a priority. As a consequence,
current smoking rates are likely to be underreported and past smoking may be conflated
with never smoking. For example, past smoking was only reported in 3/8 studies. In
China, approximately 69% of men aged 60+ years have a history of or are current
smokers, which suggests that a non-trivial proportion of past smokers for whom a
period of regular smoking earlier in life might have caused lasting disruption to the
respiratory system are not taken into account. Second, individuals with severe symptoms
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from COVID-19 may have stopped smoking prior to admission to a care facility and may
therefore not have been recorded as current smokers (i.e. reverse causality)[23]​. T hird,
smokers with COVID-19 may be less likely to present to hospital because of lack of
access to healthcare and more likely to die in the community from sudden complications
(i.e. self-selection)[23]​. Fourth, if we take at face value the observation that smoking
appears to be substantially protective against hospitalisation for COVID-19, we would
expect a female rather than male preponderance of patients in the cited studies[24]​. Fifth,
it should also be noted that smoking is a risk factor for both hypertension and diabetes,
two diseases associated with worse outcomes from COVID-19, which suggests that
current and past smoking may be both directly and indirectly implicated in COVID-19
outcomes.
 
In the UK, smoking status is systematically recorded in individuals admitted to hospital
with respiratory illnesses. We are currently in the process of developing a case-control
study based at a London acute care trust to understand the added risk of hospitalisation
due to COVID-19, compared with admission for seasonal influenza or lower respiratory
tract infections a year previous. We also plan to add relevant questions to a monthly
population survey of the general population of adults in England, and will provide up to
date statistics on www.smokinginengland.info. In the meantime, we believe that high
quality smoking cessation advice should form part of public health efforts during COVID-
19 (e.g. https://www.todayistheday.co.uk/. At the very least, smoking cessation reduces
acute risks from cardiovascular disease and could reduce demands on the healthcare
system[25]​. GPs and other healthcare providers can play a crucial role – brief, high-quality
and free online training is available at https://www.ncsct.co.uk/vba.
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